3-(吖啶-9-基氨基)-苯酚 | 51208-19-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 中文名称: 3-(吖啶-9-基氨基)-苯酚
• 英文名称: 3-(9-Acridylamino)phenol
• 英文别名: 3-acridin-9-ylamino-phenol；Phenol, m-(9-acridinylamino)-；3-(acridin-9-ylamino)phenol
• CAS: 51208-19-6
• 化学式: C₁₉H₁₄N₂O
• mdl: MFCD01707878
• 分子量: 286.333
• InChiKey: MIJMJOMZVVWZPN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.7
• 重原子数：
  22
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  45.2
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 海关编码：
  2933990090

反应信息

• 作为反应物：
  描述：

  ytterbium(III) nitrate pentahydrate 、 3-(吖啶-9-基氨基)-苯酚 以 乙醇 、 水 为溶剂， 生成
  参考文献：
  名称：

  Korovin; Rusakova; Suveizdis, Russian Journal of Inorganic Chemistry, 2002, vol. 47, # 9, p. 1398 - 1400

  摘要：

  DOI：

文献信息

• 9-anilinoacridine alkylating agents
  申请人：Su Tsann-Long

  公开号：US20080176889A1

  公开（公告）日：2008-07-24

  This invention relates to 9-anilinoacridine alkylating agents, their synthesis and their use in pharmaceutical compositions for treating diseases.

  这项发明涉及9-苯胺基吖啶烷基化剂，它们的合成以及它们在治疗疾病的药物组合物中的应用。
• [EN] NOVEL HDMX INHIBITORS AND THEIR USE FOR CANCER TREATMENT<br/>[FR] NOUVEAUX INHIBITEURS HDMX ET LEUR UTILISATION DANS LE TRAITEMENT DU CANCER
  申请人：MIRX PHARMACEUTICALS LLC

  公开号：WO2015153535A1

  公开（公告）日：2015-10-08

  The present invention provides for novel acridine-like class of compounds that have demonstrated efficiency in treating cancer. The compounds of the present invention have demonstrated efficacy in binding to and antagonizing the activity of the p53 repressor, HDMX. Once administered to a cell, the compounds of the present invention bind HDMX, thereby allowing p53 to induce apoptosis of the cancerous cell. A combination of this class of compounds along with Nutlin3 provides a novel approach to treat cancers.

  本发明提供了一种新型的类似于吖啶的化合物，已经证明可以有效地治疗癌症。本发明的化合物已经证明在结合并拮抗p53抑制剂HDMX的活性方面具有疗效。一旦这些化合物被注入细胞，它们会与HDMX结合，从而使p53诱导癌细胞凋亡。将这类化合物与Nutlin3结合使用可以提供一种治疗癌症的新方法。
• HDMX inhibitors and their use for cancer treatment
  申请人：MIRX PHARMACEUTICALS, LLC

  公开号：US10183912B2

  公开（公告）日：2019-01-22

  The present invention provides for novel acridine-like class of compounds that have demonstrated efficiency in treating cancer. The compounds of the present invention have demonstrated efficacy in binding to and antagonizing the activity of the p53 repressor, HDMX. Once administered to a cell, the compounds of the present invention bind HDMX, thereby allowing p53 to induce apoptosis of the cancerous cell. A combination of this class of compounds along with Nutlin3 provides a novel approach to treat cancers.

  本发明提供了新型吖啶类化合物，这些化合物已证明可有效治疗癌症。本发明的化合物在与 p53 抑制剂 HDMX 结合并拮抗其活性方面具有显著疗效。一旦给细胞用药，本发明的化合物就会与 HDMX 结合，从而使 p53 能够诱导癌细胞凋亡。这类化合物与 Nutlin3 的结合提供了一种治疗癌症的新方法。
• NOVEL HDMX INHIBITORS AND THEIR USE FOR CANCER TREATMENT
  申请人：MIRX PHARMACEUTICALS, LLC

  公开号：US20170022166A1

  公开（公告）日：2017-01-26

  The present invention provides for novel acridine-like class of compounds that have demonstrated efficiency in treating cancer. The compounds of the present invention have demonstrated efficacy in binding to and antagonizing the activity of the p53 repressor, HDMX. Once administered to a cell, the compounds of the present invention bind HDMX, thereby allowing p53 to induce apoptosis of the cancerous cell. A combination of this class of compounds along with Nutlin3 provides a novel approach to treat cancers.